The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson’s disease Aust. NZ J. Med., 30 (1) (2000), pp. 48-53, 10.1111/j.1445-5994.2000.tb01054.x View in ScopusGoogle Scholar Rogers et al., 2020 J.P. Rogers, E. Chesney, D. Oliver...